A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
Status:
Completed
Trial end date:
2021-03-13
Target enrollment:
Participant gender:
Summary
This drug-drug interaction (DDI) study has been designed to investigate the effect of a
moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major active
metabolite AC886.